Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment. The label supports some corticosteroid basics (prednisone as an oral corticosteroid, prednisolone as active metabolite, edema as a conceivable adverse effect, and tapering to avoid withdrawal). However, many tachycardia-specific claims are not supported by the label, and several asserted risks, onset timings, and management strategies are not documented in the labeling.
Category Scores
Accurate Statements
Prednisone is an oral corticosteroid.
DESCRIPTION / INDICATIONS
Prednisone promotes fluid retention.
ADVERSE REACTIONS
Prednisolone is the active metabolite of prednisone.
PHARMACOKINETICS
Tapering slowly is advised to avoid withdrawal.
WARNINGS AND PRECAUTIONS / DOSAGE AND ADMINISTRATION
Unsupported Statements
Prednisone can cause tachycardia (rapid heartbeat).
Absent_from_label
Tachycardia is listed as a recognized adverse reaction to prednisone, particularly at higher doses or with prolonged use.
Absent_from_label
Prednisone mimics cortisol, raising catecholamine levels (like adrenaline) and depleting potassium, both of which speed up heart rate.
Absent_from_label
Symptoms of prednisone-induced tachycardia often appear within hours to days of starting or increasing the dose.
Absent_from_label
Tachycardia affects 1-10% of users, per post-marketing data.
Absent_from_label
Tachycardia is more frequent in short-term high-dose therapy (e.g., for asthma flares or autoimmune conditions).
Absent_from_label
Elderly patients or those with heart disease face higher risk.
Absent_from_label
Stop or reduce the prednisone dose only under medical supervision—abrupt changes risk adrenal crisis.
Absent_from_label
Monitor pulse; seek immediate care if heartbeat exceeds 100 bpm at rest, with chest pain, dizziness, or shortness of breath.
Absent_from_label
Doctors may switch to alternatives or add beta-blockers.
Absent_from_label
Patients on doses over 20 mg/day have higher risk.
Absent_from_label
Those with pre-existing hypertension, arrhythmias, or hyperthyroidism have higher risk.
Absent_from_label
Long-term users (beyond 2 weeks) have cumulative effects on tachycardia risk.
Absent_from_label
Prednisone tachycardia risk is moderate (1-10%).
Absent_from_label
Prednisolone has similar tachycardia risk to prednisone.
Absent_from_label
Dexamethasone has higher tachycardia risk than prednisone.
Absent_from_label
Hydrocortisone has lower tachycardia risk than prednisone.
Absent_from_label
Hydrocortisone is shorter-acting.
Absent_from_label
Hydrocortisone IV use is common.
Absent_from_label
Heart rate typically normalizes within 24-48 hours after dose reduction or stopping prednisone.
Absent_from_label
Full recovery from tachycardia may take days to weeks if potassium is depleted.
Absent_from_label
Contradictions
Important Omissions
Label does not provide explicit tachycardia onset timing, frequency, or precise risk quantification related to prednisone use; also lacks management recommendations such as beta-blocker use or explicit monitoring thresholds.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label does not list tachycardia as a defined risk with precise timing or thresholds; edema is recognized; tapering is advised to avoid withdrawal.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Limit tachycardia-related assertions to those supported by label (e.g., edema; tapering). If tachycardia risk is to be discussed, quantify only what label supports and avoid extrapolated mechanisms or timing. Consider adding clear references to label sections for supported statements.